最新ニュース MariMed (OTC:MRMD) 株価情報

MariMed

MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees and Licensing fees.

Analyst Color

Cannabis

Market Summary

News

Penny Stocks

Small Cap Analysis

Retail Sales

Success Stories

Exclusives

Markets

Analyst Ratings

Trading Ideas

Interview

General

MRMD

シニアアナリストのPablo・Zuanic氏が、マリメド社（OTC:MRMD）CEOのJon Levine氏とのファイヤーサイドチャットを進行し、同社の事業、成長戦略および財務見通しについて透視した。この議論は、大麻投資家にとって有益な情報を提供している。

マリメド社　大麻投資家にとって重要な議論を提供

MariMed Inc

WIIM

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Shares of US-listed Chinese stocks are trading higher amid potential hopes of a China economic stimulus following Trump's election victory.

Macro Economic Events

Econ #s

Economics

Federal Reserve

DoubleLine Capital's Gundlach Says Looks To Me There Will Be Some Pressure On Interest Rates Particularly At The Long End Due To Election Results; Think Its Right To See The Trump Victory As Reducing The Odds Of Near-Term Recession Substantially; Too Early For Fed To Declare Victory On Inflation, But Could See It By March Or April

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) with a Buy and raises the price target from $61 to $68.

Price Target

RVMD

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $68

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy rating and announces Price Target of $3.

Initiation

VANI

HC Wainwright & Co. Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $3

Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares are trading higher by 6% to $44.85 this week following news of Donald Trump's victory in the <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">2024 U.S. presidential election</a>. The stock has otherwise pulled back roughly 1.2% Thursday afternoon following the The Federal Reserve&#8217;s decision to <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path">lower interest rates</a> by 0.25 percentage points.
Trump's win, coupled with a Republican-controlled Senate, has generated optimism among investors for policies that could benefit major banks and boost the financial sector broadly.
What To Know: Analysts expect that Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">proposed tax cuts</a> could lead to higher net profits for corporations, particularly large financial institutions, as they capitalize on lower tax rates. This potential increase in profitability has made Bank of America's stock more attractive to investors.
Trump's economic plan includes further relaxing financial regulations, following his previous efforts to ease provisions of the Dodd-Frank Act, which had imposed strict oversight on banks in the aftermath of the 2008 financial crisis. 
If further deregulation efforts materialize, Bank of America and other large banks may see reduced compliance costs and greater operational flexibility, enabling them to expand their lending activities and profit margins.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path">Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path</a>
What Else: Trump's plan to stimulate the economy through infrastructure spending could also increase demand for financing and investment services. As one of the largest U.S. banks, Bank of America stands to benefit from a stronger domestic economy, which could drive loan growth and improve credit conditions. 
Furthermore, Trump's trade policies, while potentially inflationary, may encourage capital flows into the U.S. banking sector, as firms look for stable financing amid global market shifts.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41819318/nasdaq-100-extends-record-levels-ahead-of-fed-meeting-tesla-hits-26-month-highs-small-caps">Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What&#8217;s Driving Markets Thursday?</a>
<h2 class="wp-block-heading">How To Buy BAC Stock</h2>
By now you're likely curious about how to participate in the market for Bank of America &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Bank of America, which is trading at $44.71 as of publishing time, $100 would buy you 2.24 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BAC has a 52-week high of $45.55 and a 52-week low of $27.34.

What's Going On With Bank Of America (BAC) Shares

HC Wainwright &amp; Co. analyst Yi Chen maintains Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Buy and raises the price target from $39 to $40.

RGNX

HC Wainwright & Co. Maintains Buy on Regenxbio, Raises Price Target to $40

HC Wainwright &amp; Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) with a Buy and raises the price target from $62 to $64.

HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $64

In the current session, the stock is trading at $173.19, after a 0.78% increase. Over the past month, Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) stock increased by 14.80%, and in the past year, by 45.93%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1731011414_0.png" alt="Past Year Chart" />

<h3>Expedia Group P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Expedia Group has a lower P/E than the aggregate P/E of 33.63 of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731011414_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

EXPE

A Look Into Expedia Group Inc's Price Over Earnings

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) with a Buy and maintains $63 price target.

Reiteration

JANX

HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $63 Price Target

Alibaba Group Holding Ltd &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares are trading higher by 4.14% to $100.75 Thursday afternoon amid hopes of <a href="https://www.benzinga.com/government/24/11/41806635/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-thursday">economic stimulus from China</a> following President-elect Donald Trump's win.
Trump's campaign promise to raise tariffs on Chinese imports up to 60% threatens to disrupt trade and trim China's GDP by one percentage point, leading Beijing to consider significant fiscal measures to support its economy.
What To Know: With the National People's Congress meeting this week, analysts expect a stimulus package potentially exceeding 10 trillion yuan ($1.39 billion), aimed at local government debt and real estate. 
For Alibaba, China's largest e-commerce and cloud company, stimulus could provide a crucial lift amid slowing consumer spending and domestic economic uncertainty. 
Enhanced financial support would likely increase consumer purchasing power, directly benefiting Alibaba's core e-commerce revenue and affiliated services like Alipay.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a>
What Else: Alibaba's gains Thursday reflect investor optimism that economic support will stabilize China's economy and offset potential losses from rising U.S. tariffs. As consumers regain confidence and spending power, Alibaba stands to benefit across its business lines, from retail to cloud computing.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path">Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path</a>
<h2 class="wp-block-heading">How To Buy BABA Stock</h2>
By now you're likely curious about how to participate in the market for Alibaba &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Alibaba, which is trading at $100.61 as of publishing time, $100 would buy you 0.99 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BABA has a 52-week high of $117.82 and a 52-week low of $66.63.

Why Alibaba Shares Are Rising

Needham analyst Scott Berg maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Buy and raises the price target from $40 to $46.

KVYO

Needham Maintains Buy on Klaviyo, Raises Price Target to $46

USDAUD

USDCAD

USDEUR

USDGBP

USDJPY

The US dollar is lower against several other currencies after the Fed cut rates.

DoubleLine Capital's Jeffrey Gundlach Says We Recommend Investors Stay In The Intermediate Part Of The Treasury Bond Market; Believe If We Keep The Price Of Oil Around Low 70s, We Are Going To See Headline Inflation Below 2% In 4-5 Months

Needham analyst Joshua Reilly reiterates HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and maintains $730 price target.

HUBS

Needham Reiterates Buy on HubSpot, Maintains $730 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

DoubleLine Capital's Jeffrey Gundlach Says Not Positive On Long-Term Treasury Bonds

Shares of Enphase Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), a leading solar energy technology provider, have fallen 17% this week amid a series of <a href="https://www.benzinga.com/quote/ENPH/earnings">analyst rating updates</a>.
Donald Trump&#8217;s re-election and GOP congressional gains signal a potential shift away from the renewable energy incentives that have bolstered the industry.
What To Know: Enphase Energy has thrived in recent years due to favorable federal and state policies promoting green energy, including tax credits that make solar systems more affordable for homeowners and businesses. 
The company has benefited from the extension of the federal solar investment tax credit and the broader clean energy policies of the Biden administration, which aligned with investor expectations for a sustained green transition. However, Trump's new term, alongside GOP legislative support, could jeopardize these subsidies.
A central component of <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41784504/trumps-win-sends-indices-to-record-highs-financials-small-caps-surge-bitcoin-tops-75-000-w">Trump's economic platform</a> is repealing various green energy tax credits, including those for solar installations, which could directly impact Enphase's core customer base. Trump has argued that these incentives distort the energy market and intends to prioritize tax breaks for fossil fuel production instead.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a>
This policy shift could result in reduced demand for solar installations if tax credits are repealed, as consumers and businesses may find it less financially viable to invest in solar energy without government assistance.
What Else: Trump&#8217;s proposed economic approach also includes rolling back environmental regulations, which could favor traditional energy sectors over renewables.
With the Republican-led Congress expected to support these policies, the likelihood of favorable conditions for fossil fuels has increased, raising concerns about competition within the energy sector.
Analysts also warn that a potential increase in trade tariffs could hurt Enphase's supply chain. Trump has committed to reimposing high tariffs on Chinese goods and implementing a 10% universal tariff on all imports.
Enphase, which sources components globally to keep production costs low, could see rising material costs under these tariffs. Higher costs would likely compress margins and challenge Enphase's pricing power, potentially making it harder to compete with fossil fuel energy sources whose production may become relatively cheaper.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path">Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ENPH has a 52-week high of and a 52-week low of

ENPH

Why Enphase Energy (ENPH) Shares Are Falling

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) with a Buy and maintains $38 price target.

LENZ

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

DoubleLine Capital's Jeffrey Gundlach Says Probably Have One More Rate Cut Coming In Dec

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

MariMed names Mario Pinho as CFO

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MariMed (OTCMKTS:<a href="https://investorplace.com/stock-quotes/mrmd-stock-quote/">MRMD</a>) just reported results for the second quarter of 2024.<ul><li>The company did not report any EPS for the quarter.</li><li>The company reported revenue of $40.44 million.</li><li>This was 2.12% better than the analyst estimate for revenue of $39.60 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mrmd-stock-earnings-marimed-for-q2-of-2024/">MRMD Stock Earnings: MariMed Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MRMD Stock Earnings: MariMed Beats Revenue for Q2 2024

MariMed Inc. (MRMD) Q2 2024 Earnings Call Transcript

MariMed (MRMD) has provided an update. MariMed Inc. has announced Mario Pinho as their new Chief Financial Officer effective August 9, 2024. With n...

MariMed Names Mario Pinho as New CFO, Enhancing Financial Leadership

American views on marijuana effects worsening: Gallup

MariMed (MRMD) announced the start of cannabis product manufacturing in Missouri. MariMed's award-winning products are expected to be available acr...

Marimed commences manufacturing operations in Missouri

InHouse, MariMed's (MRMD), is committed to serving local communities by finding ways to provide support to those in need. The mission continues thi...

Marimed's InHouse launches Help on the Homefront

Here are the major earnings after the close today

MariMed GAAP EPS of $0.00, revenue of $40.6M misses by $1.1M

MariMed Inc. (MRMD) Q3 2024 Earnings Call Transcript

AAWH

ACAD

ACLS

ADTN

AEVA

ALTO

AMPH

AMPY

AMRK

ANSS

APPS

ARAY

ARQT

ASPN

AYRWF

BBDC

BIRD

CNBS

CRLBF

CRON

CURLF

CWBHF

DUOL

ENLC

ETRGF

FLGC

GLASF

GPMT

GTBIF

HCAT

HITI

HRTG

IIPR

IONQ

JAZZ

JOBY

JUSHF

KNTK

LAND

LILA

LILAK

LOPE

LUNMF

LYFT

MAPS

MATV

MEOH

MKSI

MTCH

NDLS

NEWT

NMIH

NVGS

PCLOF

PLNH

SNDL

TCNNF

TLRY

VRNOF

YCBD

YOLO

Press Releases

MariMed Announces Opening of Second Maryland Dispensary

MariMed's Bubby's Baked Introduces New, Limited-Edition Pumpkin Bread Bites This Autumn

MariMed Commences Adult-Use Sales at Thrive Wellness Dispensary in Tiffin, Ohio

Health Care

MariMed's Betty's Eddies Partners With Keep A Breast Foundation to Promote Breast Cancer Screening Education

MariMed's Nature's Heritage Gives Local Musicians a Chance to be Featured in New Interactive Vape Campaign

MariMed Announces Third Quarter 2024 Earnings Date

MariMed Commences Cultivation Operations in Mt. Vernon, Illinois Grow Facility

MariMed Commences Manufacturing Operations in Missouri

InHouse by MariMed Launches Help on the Homefront, to Support Veterans Facing Housing Challenges

Earnings

MariMed Reports Third Quarter 2024 Earnings

CSE:MRMD

BTIG

シニアアナリストのPablo・Zuanic氏が、マリメド社（OTC:MRMD）CEOのJon Levine氏とのファイヤーサイドチャットを進行し、同社の事業、成長戦略および財務見通しについて透視した。この議論は、大麻投資家にとって有益な情報を提供している。
<h3>強い第2四半期の業績と財務見通し</h3>
Levine氏は、マリメド社が2024年第2四半期に強い<a href="https://www.benzinga.com/markets/cannabis/24/08/40250157/marimed-revenue-grows-10-7-qoq-hires-new-cfo-and-remains-on-track-to-deliver-2024-financial-targ">業績を収め、引き続き年間売上成長率の見通しを5％から7％と維持</a>していると指摘した。業界全般に圧力がかかっているにもかかわらず、マリメド社は、<a href="https://www.benzinga.com/topic/maryland-cannabis">イリノイ州</a>、<a href="https://www.benzinga.com/topic/maryland-cannabis">メリーランド州</a>、およびマサチューセッツ州での卸売業務によって、今年に至るまで11％の成長を遂げている。
Levine氏は「私たちの売上は業界全体を上回り続けており、今年と今後の見通しを達成するための準備が整っています」と語った。
また、マリメド社は中長期的な収益性への寄与を見越して、今年中にもメリーランド州における製造能力を2倍にするといった新施設への投資を行い、このために短期的なマージンとEBITDAの圧力がかかっている。
<h3>主要市場での拡大計画</h3>
マリメド社は、数々の州で事業を拡大している。同社はメリーランド州で第二の店舗を開業する予定で、これがLevine氏が年間で1,000万ドルを上回る売上を見込んでいるという。同社はベティーズ・エディーズ（Betty&#8217;s Eddies）などの人気ブランドをこの四半期末に市場に導入する予定で、ミズーリ州でも加工免許を取得している。
マサチューセッツ州においてもマリメド社は、同社の強いブランド認知度を通じて、市場シェアを拡大している。Levine氏は、「ブランド認知度と製品の品質のおかげで、私たちのマサチューセッツ州での卸売りビジネスは成長を続け、誰もが驚いています」と述べた。
関連記事： <a href="https://www.benzinga.com/markets/cannabis/24/08/40322027/trumps-flip-on-marijuana-legalization-conflicts-with-running-mate-jd-vance-who-does-not-share-th">トランプ氏、大麻解禁を巡る考えが変化 トランプ氏のランニングメイトJDヴァンス氏との間で見解が相違</a>
また、マリメド社はイリノイ州とオハイオ州での小売り事業の拡大にも注力している。同社はイリノイ州で5店舗を運営しており、さらに5店舗を追加する予定である。また、オハイオ州では、州が最近成人向け大麻の販売を開始したため、マリメド社も事業を拡大する準備を整えている。
<h3>M&amp;Aとライセンスを通じた将来の成長</h3>
Levine氏は、マリメド社が進めている企業買収（M&amp;A）とライセンス契約に関する活動についても語った。同社はライセンス料が高すぎないかという点には慎重であるが、<a href="https://www.benzinga.com/topic/ohio-cannabis">オハイオ州</a>、ミズーリ州および他の州での事業拡大の機会を積極的に模索しているという。Levine氏はまた、ニューヨーク州、テキサス州、バージニア州でのライセンス申請についても言及している。
マリメド社は、現在事業を展開していないロードアイランド州やプエルトリコなどの州でのライセンスの取得についても検討している。ただしLevine氏は、マリメド社の製品の高品質と一貫性を維持するためには、適切なパートナーを見つけることが重要であると強調した。
<h3>政治的見通し：大統領選挙と大麻</h3>
一方でLevine氏はファイヤーサイドチャットの中で、大麻の再分類に関する元大統領ドナルド・トランプ氏の最近のコメントについての質問に答えた。 Levine氏は、大麻の再分類についての議論が民主党と共和党の双方で増加していることに関して楽観的な見方を示し、「再分類は次の12か月以内に何らかの形で実現すると思います」と述べた。ただし、Levine氏は政府の行動が鈍いことを認めた。
次の記事を読む： <a href="https://www.benzinga.com/markets/cannabis/24/08/40271940/trump-says-its-hard-to-have-people-all-over-the-jails-for-cannabis-offenses-as-he-hints-at-legal">再分類された大麻に対してトランプ氏、法的処置を取ることを示唆</a>
<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a>
。

Comments

MariMed

ニュース

最新ニュース MariMed (OTC:MRMD) 株価情報

月曜日, 8 12, 2024

ニュース

パートナーシップ

ベンジンガ・グローバル